Chika Nitani1, Junichi Hara2, Hiroshi Kawamoto3, Tomoaki Taguchi4, Toshimi Kimura5, Kenichi Yoshimura6, Akinobu Hamada7, Shigehisa Kitano8, Naoko Hattori9, Toshikazu Ushijima9, Hiromi Ono10, Masako Nakamoto10, Tsukiko Higuchi10, Akihiro Sato10. 1. Department of Pediatric Hematology and Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka, 534-0021, Japan. c-tanaka@med.osakacity-hp.or.jp. 2. Department of Pediatric Hematology and Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka, 534-0021, Japan. 3. Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan. 4. Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 5. Department of Pharmacy, Tokyo Women's Medical University Hospital, Tokyo, Japan. 6. Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima, Japan. 7. Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan. 8. Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. 9. Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan. 10. Clinical Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
Abstract
PURPOSE: Tamibarotene is a synthetic retinoid that inhibits proliferation and induces differentiation of malignant cells by binding to the retinoic acid receptor α/β. Previous in vitro studies have shown that some pediatric solid tumors with retinoic acid receptors differentiate in response to retinoic acid. We conducted a phase I dose-escalation study to determine the recommended dose of tamibarotene for further study in pediatric and young adult patients with recurrent/refractory solid tumors. METHODS: Pediatric and young adult patients with recurrent/refractory solid tumors were administered tamibarotene at 4, 6, 8, 10, and 12 mg/m2/day for 14 or 21 days of a 28 day cycle. Safety, efficacy, and pharmacokinetics of tamibarotene were evaluated. RESULTS: Twenty-two patients (median age 8 years) were enrolled in this study. No dose-limiting toxicity (DLT) was encountered, and tamibarotene was generally well tolerated. Two patients experienced severe adverse events (AEs), leading to discontinuation of the treatment. One grade 4 venous thrombosis and one grade 2 erythema multiforme were observed, which promptly resolved after tamibarotene discontinuance. The grade 4 venous thrombosis was a severe AE but not DLT because it occurred after the evaluation period. Pharmacokinetic analyses showed a dose-dependent increase in the maximum drug concentration (Cmax) and area under the concentration-time curve (AUC). None of the patients achieved a complete response or partial response. Seven patients had stable disease lasting longer than 18 weeks. CONCLUSIONS: The recommended dose for phase II study of tamibarotene in pediatric and young adult patients with refractory solid tumors is 12 mg/m2/day for 21 days in a 28 day cycle.
PURPOSE:Tamibarotene is a synthetic retinoid that inhibits proliferation and induces differentiation of malignant cells by binding to the retinoic acid receptor α/β. Previous in vitro studies have shown that some pediatric solid tumors with retinoic acid receptors differentiate in response to retinoic acid. We conducted a phase I dose-escalation study to determine the recommended dose of tamibarotene for further study in pediatric and young adult patients with recurrent/refractory solid tumors. METHODS: Pediatric and young adult patients with recurrent/refractory solid tumors were administered tamibarotene at 4, 6, 8, 10, and 12 mg/m2/day for 14 or 21 days of a 28 day cycle. Safety, efficacy, and pharmacokinetics of tamibarotene were evaluated. RESULTS: Twenty-two patients (median age 8 years) were enrolled in this study. No dose-limiting toxicity (DLT) was encountered, and tamibarotene was generally well tolerated. Two patients experienced severe adverse events (AEs), leading to discontinuation of the treatment. One grade 4 venous thrombosis and one grade 2 erythema multiforme were observed, which promptly resolved after tamibarotene discontinuance. The grade 4 venous thrombosis was a severe AE but not DLT because it occurred after the evaluation period. Pharmacokinetic analyses showed a dose-dependent increase in the maximum drug concentration (Cmax) and area under the concentration-time curve (AUC). None of the patients achieved a complete response or partial response. Seven patients had stable disease lasting longer than 18 weeks. CONCLUSIONS: The recommended dose for phase II study of tamibarotene in pediatric and young adult patients with refractory solid tumors is 12 mg/m2/day for 21 days in a 28 day cycle.
Entities:
Keywords:
Dose-limiting toxicity; Pediatric and young adult solid tumors; Pharmacokinetics; Retinoic acid; Tamibarotene
Authors: Jason W Barlow; Joe C Wiley; Marieke Mous; Aru Narendran; Matthew F W Gee; Michael Goldberg; Elizabeth Sexsmith; David Malkin Journal: Pediatr Blood Cancer Date: 2006-11 Impact factor: 3.167
Authors: K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544